Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial by Muntau, Ac et al.
Muntau et al. Orphanet Journal of Rare Diseases  (2017) 12:47 
DOI 10.1186/s13023-017-0600-xRESEARCH Open AccessEfficacy, safety and population
pharmacokinetics of sapropterin in PKU
patients <4 years: results from the SPARK
open-label, multicentre, randomized phase
IIIb trial
Ania C. Muntau1*, Alberto Burlina2, François Eyskens3, Peter Freisinger4, Corinne De Laet5, Vincenzo Leuzzi6,
Frank Rutsch7, H. Serap Sivri8, Suresh Vijay9, Milva Orquidea Bal10, Gwendolyn Gramer11, Renata Pazdírková12,
Maureen Cleary13, Amelie S. Lotz-Havla14, Alain Munafo15, Diane R. Mould16, Flavie Moreau-Stucker17
and Daniela Rogoff17Abstract
Background: Sapropterin dihydrochloride, a synthetic formulation of BH4, the cofactor for phenylalanine
hydroxylase (PAH, EC 1.14.16.1), was initially approved in Europe only for patients ≥4 years with BH4-responsive
phenylketonuria. The aim of the SPARK (Safety Paediatric efficAcy phaRmacokinetic with Kuvan®) trial was to assess
the efficacy (improvement in daily phenylalanine tolerance, neuromotor development and growth parameters),
safety and pharmacokinetics of sapropterin dihydrochloride in children <4 years.
Results: In total, 109 male or female children <4 years with confirmed BH4-responsive phenylketonuria or mild
hyperphenylalaninemia and good adherence to dietary treatment were screened. 56 patients were randomly assigned
(1:1) to 10 mg/kg/day oral sapropterin plus a phenylalanine-restricted diet or to only a phenylalanine-restricted diet for
26 weeks (27 to the sapropterin and diet group and 29 to the diet-only group; intention-to-treat population). Of these,
52 patients with ≥1 pharmacokinetic sample were included in the pharmacokinetic analysis, and 54 patients were
included in the safety analysis. At week 26 in the sapropterin plus diet group, mean phenylalanine tolerance was 30.5
(95% confidence interval 18.7–42.3) mg/kg/day higher than in the diet-only group (p < 0.001). The safety profile of
sapropterin, measured monthly, was acceptable and consistent with that seen in studies of older children. Using non-
linear mixed effect modelling, a one-compartment model with flip-flop pharmacokinetic behaviour, in which the effect
of weight was substantial, best described the pharmacokinetic profile. Patients in both groups had normal neuromotor
development and stable growth parameters.
Conclusions: The addition of sapropterin to a phenylalanine-restricted diet was well tolerated and led to a
significant improvement in phenylalanine tolerance in children <4 years with BH4-responsive phenylketonuria
or mild hyperphenylalaninemia. The pharmacokinetic model favours once per day dosing with adjustment
for weight. Based on the SPARK trial results, sapropterin has received EU approval to treat patients <4 years with
BH4-responsive phenylketonuria.
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Hyperphenylalaninemia (HPA) is a rare inherited meta-
bolic disorder caused by reduced activity of the hepatic
enzyme phenylalanine hydroxylase (PAH, EC 1.14.16.1),
which catalyses the conversion of phenylalanine (Phe) to
tyrosine. Most cases of HPA (98%) in North American
and European populations are due to mutations in the
PAH gene but, in rare cases of HPA (1–2%), the cause
can be a defect in the metabolism of the natural PAH
cofactor, the R diastereoisomer of tetrahydrobiopterin
(BH4) [1–3]. Owing to the reduced activity of PAH due
to either mechanism, patients with HPA have an accu-
mulation of Phe in the blood and body tissues and a
relative deficiency of tyrosine and subsequent metabo-
lites such as epinephrine [4, 5].
HPA can present with a spectrum of phenotypes that
can be grouped into three main categories according to
blood Phe concentrations before therapeutic intervention:
classical PKU (Phe >1200 μmol/L); mild PKU (Phe 600–
1200 μmol/L); mild HPA (Phe 120–600 μmol/L) [2, 5, 6].
PKU can lead to cognitive impairment and, if untreated,
patients can develop mild-to-severe intellectual disability
and other neurological sequelae [2, 5, 7].
The therapeutic range of Phe concentration varies
according to different guidelines [8, 9], and there is no
international consensus. The US diagnostic and manage-
ment guidelines recommend that the initiation of treat-
ment for PKU should be undertaken as early as possible,
preferably within the first week after birth, with a goal of
having blood Phe in the range 120–360 μmol/L within
the first 2 weeks of life, to prevent permanent neuro-
logical damage [10]. The European guidelines recom-
mend target concentrations of 120-360 μmol/L for
individuals aged 0-12 years and for maternal PKU [11].
In both, this is largely achieved by a natural protein-
restricted diet and Phe-free synthetic amino-acid supple-
mentation [10, 11]. However, adherence to a Phe-restricted
diet is burdensome owing to the need for long-term dietary
counselling and daily micronutrient supplementation [12].
The management guidelines also stipulate that a course of
treatment with BH4 should be investigated [10, 11].
Sapropterin dihydrochloride (sapropterin, Kuvan®, Merck,
Geneva, Switzerland, an affiliate of Merck KGaA,
Darmstadt, Germany, and BioMarin, Novato, CA, USA) is
a synthetic formulation of BH4 that has been shown to be
effective in lowering serum Phe concentrations and/or im-
proving dietary Phe tolerance in a subset of patients with
PKU or mild HPA who respond to treatment with BH4
(known as responders) and in the rare patients with a de-
fect in BH4 synthesis [12]. Based on the results of the
SPARK (Safety Paediatric efficAcy phaRmacokinetics with
Kuvan®) study, the European Medicines Agency has re-
cently extended the indication for sapropterin from the
treatment of BH4-responsive PKU in adults and childrenaged ≥4 years and in all BH4-deficient adults and children
[12, 13] to now include children with BH4-responsive
PKU <4 years old, for whom the previous standard of care
was a Phe-restricted diet.
The primary aim of the SPARK study was to evaluate
the efficacy (increase in Phe tolerance, defined as the
amount of Phe a patient may consume while maintain-
ing blood Phe concentrations within the target range of
120–360 μmol/L); safety of 26 weeks of treatment with
sapropterin dihydrochloride plus a Phe-restricted diet
compared with a Phe-restricted diet alone in children
<4 years of age with BH4-responsive PKU or mild HPA;
to document the relationship between exposure and re-
sponse; and to support the posology in this age-group.
Although population pharmacokinetic (PopPK) data for
sapropterin have been published for infants and young
children in the USA and Canada [14], there are no
PopPK data for sapropterin in this age range in the
European Union (EU); therefore, a secondary aim of
SPARK was to develop a PopPK model for sapropterin
in this population. The other secondary endpoints were
to document the concentrations of blood Phe during the
study and extension periods, to document the change in
dietary Phe tolerance, and to monitor blood pressure,
growth parameters, and neuromotor developmental
milestones.
Methods
Study design
The SPARK trial (NCT01376908) is a 26-week open-
label, multicentre, randomized phase IIIb study to assess
the efficacy, safety and PopPK of sapropterin in patients
aged <4 years with BH4-responsive PKU or mild HPA.
SPARK was conducted at 22 sites in nine countries:
Austria (n = 2), Belgium (n = 2), Czech Republic (n = 1),
Germany (n = 4), Italy (n = 5), Netherlands (n = 2),
Slovakia (n = 3), Turkey (n = 1) and the United Kingdom
(n = 2). The study was performed in accordance with the
protocol and subsequent protocol amendments and with
the ethical principles laid down in the Declaration of
Helsinki, in accordance with the International Confer-
ence on Harmonisation (ICH), Note for Guidance on
Good Clinical Practice (ICH Topic E6, 1996) and applic-
able regulatory requirements. The local ethics commit-
tee/institutional review board at each of the participating
centres approved the protocol.
Patients
Male or female patients aged <4 years at randomization
were eligible for entry into the study if they had participated
in the screening protocol <42 days before study day 1, had
a confirmed diagnosis of mild HPA or PKU (a defined level
of Phe tolerance consistent with a diagnosis of PKU, ≥2
previous blood Phe concentrations ≥400 μmol/L obtained
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crease of >30% in Phe concentrations following a 20 mg/kg
BH4 challenge of at least 24 h), good adherence to dietary
treatment and maintenance of blood Phe concentrations
within the therapeutic target range (120–360 μmol/L) for
4 months prior to screening or at least the last four values
of Phe (either from venous blood or dry blood spot) were
to be assessed, out of which 75% had to be within the above
therapeutic range. Patients were excluded if they had used
sapropterin or any preparation of BH4 within the previous
30 days (unless for the purposes of the BH4 responsive-
ness test), had known hypersensitivity to sapropterin,
its excipients, or to other approved or non-approved
formulations of BH4, or had a previous diagnosis of
BH4 deficiency.
Patients’ parent(s)/guardian(s) gave written informed
consent for participation in the study before any trial-
related procedures were performed. Parent(s) and/or
guardian(s) had to be willing to comply with all study
procedures, maintain strict adherence to the diet, and be
willing and able to provide written, signed informedFig. 1 Patient disposition. *Two of the randomized patients withdrew cons
the study periodconsent after the nature of the study had been explained
and prior to any study procedures. Where required,
separate informed consent was obtained from the
patients’ parents or guardians to obtain samples for
pharmacokinetic analysis.
Randomization
On study day one, patients were randomly assigned 1:1
to 10 mg/kg/day oral sapropterin dissolved in water to
be taken with breakfast (after 4 weeks, sapropterin could
be increased to 20 mg/kg/day if Phe tolerance had not
increased by >20% vs. baseline) plus a Phe-restricted diet
or only a Phe-restricted diet for 26 weeks. After study
completion, patients were eligible to enrol in a 3-year
extension period (to be reported separately), during
which all patients received sapropterin plus a Phe-
restricted diet (Fig. 1).
Efficacy assessments
The primary outcome was an improvement in dietary
Phe tolerance, defined as the daily amount of Phe (mg/ent after randomization. No safety assessments were performed during
Table 1 Algorithm for phenylalanine (Phe) intake adjustments
according to mean Phe concentrations
Mean Phe
concentration, μmol/L
Phe intake adjustment
At Week 2
0–300 Increase by 5 mg/kg/day
301–359 No adjustment required
360–∞ No adjustment required, but monitor
concentration at next visit
Post-Week 2
0–180 Increase by 15 mg/kg/day
181–240 Increase by 10 mg/kg/day
241–300 Increase by 5 mg/kg/day
301–359 No change in dietary Phe intake
360–∞ Determine if the subject had one or
more previous dietary Phe intake increases
• If so, remove the dietary Phe in the order
that it was previously increased, beginning
with the amount of the last increase
• If not, no adjustment required
360–1199 If this is first occasion at this concentration,
monitor concentration at the next visit and
if second occasion is at this concentration,
provide dietary counseling
1200–∞ If this is first occasion at this concentration,
provide dietary counseling and monitor
concentration at the next visit and if second
occasion is at this concentration, provide
dietary counseling and terminate from the trial
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blood Phe concentrations within a target range of 120–
360 μmol/L by dietary Phe adjustments following an al-
gorithm (Table 1). An additional supportive analysis was
performed, in which dietary Phe tolerance was based on
the Phe intake reported in a 3-day Phe diet diary used to
monitor the adherence to the Phe-restricted diet. Ana-
lysis and adjustment of dietary intake were performed by
the investigator and/or experienced dietician/nutritionist
every 2 weeks during the study, according to the study
algorithm.
Blood Phe concentrations were measured twice weekly
via dried blood spot cards using a high-performance liquid
chromatography/tandem mass spectrometry method for
Phe detection. The results were verified every 3 months
using venous blood plasma. Blood Phe samples could be
obtained more frequently at the investigator’s discretion.
Secondary endpoints included neuromotor develop-
ment and physical growth parameters (height or length,
weight and maximal occipital-frontal head circumfer-
ence). Neuropsychological development was assessed
using the adaptive behaviour composite score with the
Bayley III and the social-emotional composite score in
the WPPSI-III, although these results are not reported
in this manuscript.Pharmacokinetic analysis
The PopPK analysis population comprised all randomized
subjects with ≥1 pharmacokinetic sample. PopPK parame-
ters were apparent clearance (CL/F), apparent volume of
distribution (V/F), absorption rate constant (Ka), and en-
dogenous BH4 (C0). These were used to compute the area
under the curve (AUC0–∞), peak serum concentration
(Cmax), time of Cmax (Tmax), and half-life (t1/2). Plasma
samples were collected for endogenous BH4 measurement
at baseline and sparsely thereafter between weeks 5–12
after oral administration of sapropterin 10 mg/kg/day. In
order to ensure that the sparse pharmacokinetic sampling
provided sufficient information and that samples were
taken at informative times, the sampling had been planned
using D-optimization [15]. During this process, competing
maturation functions were considered [16, 17].
PopPK modelling was conducted using NONMEM®
(software version 7, level 2; Icon Development Solutions,
Ellicott City, MD, USA) using standard model building
and evaluation approaches. Covariates, including age,
weight and sex, were evaluated using standard method-
ology to determine if these factors were predictive of BH4
pharmacokinetics. The final model was subsequently used
to derive metrics of exposure and to determine the expos-
ure relative to adult PKU patients.
Laboratory assessments
All standard blood chemistry, hematologic and urine ana-
lysis, as well as specialized testing for Phe and tyrosine
concentrations, were performed at a central laboratory.
Safety analysis
The safety population consisted of all subjects who had
some safety assessment data available. Safety was assessed
at the clinic on a monthly basis during the 26-week study
period or until 4 weeks post-treatment, by recording,
reporting, and analysis of baseline medical conditions
and adverse events (AEs) and physical examination
findings (including vital signs). Standard blood chemis-
try, hematologic, and urine analyses were performed
every 3 months during the study period for safety
analysis.
Genotype analysis
PAH genotype data were collected at screening for
enrolled patients, after a separate informed consent was
obtained from the patients’ parents or guardians. Geno-
type testing was performed by a central laboratory.
Statistical analyses
The primary efficacy analysis population was the
intention-to-treat (ITT) population comprising all ran-
domized patients. The per-protocol (PP) population in-
cluded all ITT patients who completed the study with
Table 2 Demographic and baseline characteristics (ITT
population)
Characteristic Sapropterin + Phe-
restricted diet (n = 27)
Phe-restricted
diet only (n = 29)
Age, months
mean±SD 21.1±12.3 21.2±12.0
min; max 2; 47 2; 44
Age group, n (%)
<12 months 7 (25.9) 8 (27.6)
12 − <24 months 9 (33.3) 9 (31.0)
24 − <48 months 11 (40.7) 12 (41.4)
Males, n (%) 16 (59.3) 14 (48.3)
Height, cm
mean±SD 82.0±11.3 82.3±11.6
min; max 59; 108 57; 105
Weight, kg
mean±SD 11.3±3.1 11.3±2.8
min; max 5; 20 6; 16
BMI, kg/m2
mean±SD 16.5±1.0 16.5±1.4
min; max 14; 18 14; 20
Age at PKU diagnosis, days
mean±SD 27.2±79.8 32.6±72.2
min; max 1; 425 4; 382
Blood Phe concentration at diagnosis, μmol/L
mean±SD 780.3±480.7 879.9 ± 596.5
min; max 191; 2062 221; 2600
PKU severitya n (%)
Classical PKU 5 (18.5) 7 (24.1)
Mild PKU 10 (37.0) 8 (27.6)
Mild HPA 12 (44.4) 14 (48.3)
BMI body mass index, HPA hyperphenylalaninemia, ITT intention-to-treat, Phe
phenylalanine, PKU phenylketonuria, SD standard deviation
aDisease severity according to blood Phe concentrations: Classical PKU,
>1200 μmol/L; Mild PKU, 600–1200 μmol/L; Mild HPA, 120–600 μmol/L2, 5, 6
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major protocol deviation. A missing pre-study Phe toler-
ance, lack of adherence to Phe-restricted diet over the
past 3 months, lack of adherence to sapropterin, and a
sapropterin-dose adjustment not conducted as per
protocol were considered to be major protocol devia-
tions leading to exclusion from the PP population. The
safety population comprised all patients with safety as-
sessment data available (≥1 visit for vital signs, AEs or
laboratory results) and who had received ≥1 dose of
sapropterin or were randomly assigned to Phe-restricted
diet alone.
The sample size was planned to be 23 patients per group,
to ensure a power of 80% to demonstrate a treatment group
difference, assuming a dietary Phe tolerance of 20 mg/kg/
day under dietary therapy alone, a difference of 75% with
the sapropterin plus diet group, and a common standard
deviation of 17.5 mg/kg/day. To compensate for possible
dropouts, a total of 50 subjects were to be randomized.
The dietary Phe tolerance was analyzed using the re-
peated measures analysis of covariance (ANCOVA) on
the observed records for the ITT population, with base-
line Phe tolerance, treatment group, age group, visit,
baseline blood Phe concentration and treatment by visit
interaction as fixed effects. Secondary endpoints were
described using summary statistics.
Non-linear mixed-effect modelling (NONMEM® soft-
ware version 7, level 2) was applied to estimate the
pharmacokinetic parameters and their variability. The
final model was evaluated using a number of methods,
which included bootstrapping and visual predictive
checks, as conducted previously in children aged 0–6
years [18].
In order to evaluate the differences in exposure ex-
pected from the original model and the current model,
simulated concentration–time profiles for the reference
subject were generated.
Results
Patient disposition and demographics
In total, 109 patients were screened (Table 2 and Fig. 1),
of whom 53 were screening failures (49 patients did not
meet eligibility criteria and four patients for other
reasons). Fifty-six patients were randomized (27 patients
to the sapropterin plus Phe-restricted diet group and
29 patients to the diet-only group). Fifty-two patients
were included in the PopPK population. Patients were
stratified according to age: 15 patients were <12 months,
18 patients were 12 to <24 months, and 23 patients
were 24 to <48 months. A numerically higher propor-
tion of patients in the sapropterin plus Phe-restricted
diet group successfully followed the protocol compared
with patients in the Phe-restricted diet only group (85%
[23 of 27 patients] vs. 65% [19 of 29 patients]). Themean (±standard deviation [SD]) age at diagnosis was
30 (±75.3) days. Almost half (46.4%) were diagnosed
with mild HPA, 32.1% were diagnosed with mild PKU,
and 21.4% were diagnosed with classical PKU.
The overall mean adherence to sapropterin (defined as
the proportion between the actual dose administered
and the prescribed dose) over the study was 100% (range
82 to 107%). Most patients (n = 25, 92.6%) continued on
10 mg/kg/day after 4 weeks of treatment, with only two
patients switching to 20 mg/kg/day. The overall mean
(±SD) adherence to diet, as assessed by a 3-day food
diary, was 94.6±9.4% (range 69 to 111%) in the
sapropterin-treated group and 92.1±23.8% (range 65 to
183%) in the diet-only treated group.
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At week 26, the adjusted mean dietary Phe tolerance
was higher in the sapropterin plus Phe-restricted diet
group compared with the diet-only group. The toler-
ance based on prescribed Phe was 80.6 mg/kg/day vs.
50.1 mg/kg/day (adjusted between-group difference
30.5 mg/kg/day [95% confidence interval (CI) 18.7,
42.3], p < 0.001). The tolerance based on reported
dietary Phe tolerance from the intake diary was
75.7 mg/kg/day [95% CI 67.2, 84.11] vs. 42.0 mg/kg/day
[95% CI 33.1, 50.8] (adjusted between-group difference
33.7 [95% CI 21.4, 45.9], p < 0.001; Fig. 2a). A similar
difference was reported in the per-protocol population
(adjusted between-group difference 36.4 [95% CI 25.4,
47.4], p < 0.001). In addition, consistent results were
seen in the ITT population following supportive ana-
lysis on diary-recorded Phe intake.
Blood Phe concentrations
Phe concentrations from dried blood spots were lower
than those from venous blood spots but this was consist-
ent with differences reported in the literature [19–21].
In the Phe-restricted diet group, the adjusted mean
blood Phe concentrations in the ITT population were
stable over time, with a mean (±SD) increase of 23.1
(±21.9) μmol/L at week 26 (Fig. 2b). In the sapropterinFig. 2 a Adjusted mean dietary Phe tolerance (mg/kg/day) a and mean Ph
confidence intervals. Phe, phenylalanine. CI, confidence interval; Phe, phenyplus Phe-restricted diet group, the mean (±SD) blood
concentrations decreased by 110.7 (±20.1) μmol/L at
week 4 and gradually returned to concentrations similar
to those seen in the Phe-restricted diet group, reflecting
the increase in Phe intake and Phe tolerance. At week 26,
the adjusted mean (±SD) blood Phe concentrations were
similar: 300.1 (±115.2) μmol/L in the sapropterin plus
Phe-restricted diet group and 343.3 (±118.4) μmol/L in
the diet-only group (adjusted between-group difference
33.2 μmol/L [95% CI −94.8, 28.4], p = 0.290). It is im-
portant to note that patients were expected to maintain
blood Phe concentrations within this range; therefore,
differences in blood Phe concentrations were not
anticipated.
The observed proportion of patients with blood Phe
concentrations maintained in the range 120–360 μmol/L
throughout the whole study was greater in the saprop-
terin plus Phe-restricted diet group (n = 9/27, 33.3%)
than in the diet-only group (n = 3/29, 10.3%). 21 of 27
(77.8%) sapropterin-treated patients and 15 of 27 (55.6%)
patients on only the Phe-restricted diet had ≥1 blood
Phe concentration at or below the 120 μmol/L thresh-
old established by the British PKU Registry [22]. How-
ever, very few instances of Phe concentration below the
normal range thresholds of 40 and 26 μmol/L were ob-
served during the study.e change from baseline (μmol/L) b Error bars represent 95%
lalanine
Fig. 3 Relationship between weight and clearance a and weight
and volume of distribution b
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The mean change in dietary Phe tolerance between baseline
and the last Phe tolerance observation was assessed within
each treatment group. The mean (±SD) change from base-
line to week 26 in patients receiving sapropterin plus
Phe-restricted diet was 36.9 (±27.3) mg/kg/day (p < 0.001).
The mean change from baseline in patients only on the
Phe-restricted diet was 13.1 (±19.6) mg/kg/day (p = 0.002).
Pharmacokinetic analysis
The pharmacokinetic data are best described by a one-
component model with first-order input following a time
lag and first-order elimination, with an endogenous
baseline BH4 concentration component. The model in-
cluded terms describing between-subject variability on
apparent clearance (CL/F) and apparent volume of dis-
tribution (V/F) as well as their correlation (Table 3). The
final model parameter estimate for CL/F was 2780 L/h,
3870 L for V/F, and 0.234 h−1 for Ka.
From the model, an elimination half-life of approxi-
mately 1 h can be computed, with an absorption half-life
(ln2/Ka) of approximately 3 h, suggesting flip-flop kinet-
ics where the absorption becomes the rate-limiting step
of drug disposition.
Body weight was the only covariate that affected the
CL/F and V/F of sapropterin: these variables increased
in a nonlinear manner with increasing weight, although
individual predictions still varied around the typical
individual predictions (Fig. 3). At the lowest extreme of
weight, a 5 kg patient had a CL/F value 11% of that of a
70 kg reference adult, and a V/F value 22% of that of the
reference adult (Table 4).
Even after inclusion of weight into the pharmacoki-
netic model, significant between-subject variability inTable 3 Parameter estimates for final model
Population mean SE%
CL/F (L/h) 2780 2.0
V/F (L) 3870 5.9
Ka (1/h) 0.234 6.6
LAG (h) 0.342 2.8
C0 (μg/L) 12.6 7.8
Coefficient describing effect of weight on CL/F 0.839 1.8
Coefficient describing effect of weight on V/F 0.573 3.3
Residual error (%CV) 65.30 8.5
IIV_CL (%CV) 22.98 0.2
IIV_V2 (%CV) 32.56 0.2
Corr (CL,V) 0.134 NE
SE standard error, CL/F apparent clearance, V/F apparent volume of
distribution, LAG, lag time, Ka absorption rate constant, C0 endogenous BH4
concentrations, CV coefficient of variation, IIV between-subject variability, NE
not estimatedCL/F and V/F remained, supporting an adaptive ap-
proach to individual treatment. Simulated concentra-
tion–time curves following sapropterin 10 mg/kg show
that sapropterin concentrations remain above the model-
estimated endogenous BH4 concentrations (12.6 μg/L;
Table 3) for the dose interval for patients with different
weights (Fig. 4).
Overall, the exposure across all age groups is compar-
able, although the number of patients in all age groups
is small. The exposure in pediatric patients was lower
than the expected exposure in adults, based on the
simulated concentration–time profiles following the
10 mg/kg/day dose across a range of body weights. This
analysis shows that the concentrations remain above the
endogenous concentration, which is set at a concentrationTable 4 Effect of weight on clearance and volume of
distribution
Weight (kg) CL/F (L/h) % of reference V/F (L) % of reference
5 305 10.9 853 22.0
15 766 27.5 1601 41.4
25 1176 42.2 2145 55.4
70a 2789 100.0 3870 100.0
CL/F apparent clearance, V/F apparent volume of distribution
aReference weight (adult male patient)
Fig. 4 Simulated concentration–time curves for patients with various weights following sapropterin (10 mg/kg/day)
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daily dose interval and support the current approach to
treatment as conservative (Fig. 4).
Safety
The safety population comprised 54 patients; two of the
randomized patients withdrew consent after randomizationTable 5 Summary of safety data showing the proportion of patients
Sapropterin +
Patients, n (%
Treatment-emergent AEs 27 (100)
AEs related to sapropterin 8 (29.6)
Infections and infestations related to sapropterin 3 (11.1)
Gastrointestinal disorders related to sapropterin 3 (11.1)
Amino acid concentrations decrease related to sapropterin 6 (22.2)
SAEs 3 (11.1)
Gastroenteritis 1 (3.7)
Rash 1 (3.7)
Overdosea 1 (3.7)
Stomatitis 1 (3.7)
Bronchiolitis 0 (0.0)
Bronchopneumonia 0 (0.0)
AEs leading to discontinuation 0 (0.0)
NA not appropriate, SAE serious AE
aOn the day of first administration of study treatment, the subject had a sapropteri
26 days after the first administration of study treatment, the subject had another sa
mistake). Both events were reported in accordance with the protocol and were the
sequelae from both events. The administration of sapropterin plus Phe-restricted di
was reduced after the second overdose
AE defined as any untoward medical occurrence in a subject or clinical investigatio
have a causal relationship with trial treatment; SAE was any untoward medical occu
caused death if it had been more severe; required inpatient hospitalization or prolo
disability/incapacity; was a congenital anomaly/birth defect; or was otherwise consiand, therefore, were excluded from the safety population
(Fig. 1). All patients in the safety population reported at
least one AE (Table 5); in the sapropterin plus Phe-
restricted diet group, eight out of 27 patients (29.6%) re-
ported at least one treatment-emergent AE (TEAE) classi-
fied as related to sapropterin. The proportion of patients
reporting TEAEs was the same in the two groups, and noreporting adverse events (AEs) (Safety population)
Phe-restricted diet (n = 27) Phe-restricted diet alone (n = 27)
) Events, n Patients, n (%) Events, n
282 27 (100) 278
31 NA NA
3 NA NA
8 NA NA
20 NA NA
5 1 (3.7) 2
1 0 (0.0) 0
1 0 (0.0) 0
2 0 (0.0) 0
1 0 (0.0) 0
0 1 (3.7) 1
0 1 (3.7) 1
0 0 (0.0) 0
n overdose (severity: mild; 80 mg/day instead of 75 mg/day by mistake). At
propterin overdose (severity: mild; 80 mg/day instead of 75 mg/day by
refore categorized as medically important. The subject recovered without
et alone was continued without change after the first overdose and the dose
n subject administered a pharmaceutical product, which did not necessarily
rrence that at any dose: resulted in death; was life-threatening; might have
ngation of existing hospitalization; resulted in persistent or significant
dered as medically important
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graded as severe. All patients had at least one TEAE that
was judged to be mild in severity. Seven (25.9%) patients in
the sapropterin plus Phe-restricted diet group had nine
TEAEs graded as moderate in severity, and eight (29.6%)
patients in the Phe-restricted diet group reported 18 TEAEs
graded as moderate in severity.
The most common TEAEs in the sapropterin plus
Phe-restricted diet group and in the Phe-restricted diet
group were: pyrexia (63.0 and 66.7%), cough (48.1 and
48.1%) and nasopharyngitis (48.1 and 40.7%), respectively.
The most common TEAEs classified as related to saprop-
terin were amino acid concentration decrease (six patients
[22.2%]), rhinitis, and vomiting (two patients each [7.4%]),
and one patient (3.7%) each for pharyngitis, diarrhea,
abdominal pain, mouth ulceration and increased amino
acid concentration.
Although the proportion of patients who reported a
serious AE (SAE) was higher in the sapropterin plus
Phe-restricted diet group compared with the Phe-restricted
diet (11.1 vs. 3.7%), all SAEs were assessed as unrelated to
sapropterin treatment (Table 5).
Genotype data
Of 109 patients who were screened, 73 agreed to partici-
pate in the pharmacogenetics sub-study. Of the 73 patients
who agreed, 36 were screening failures, leaving genotype
data for 37 responders (Additional file 1: Table S1).
Neuromotor development and growth parameters
Most patients in both treatment groups had normal neuro-
motor development, including fine motor, gross motor,
language, and personal and social function, and there were
no statistically significant differences between treatment
groups in any of the neuromotor developmental milestones
at baseline, 12 and 26 weeks (Additional file 1: Figure S1).
Patients in both treatment groups had stable growth
parameters, including body mass index SD score (SDS),
height SDS, maximum occipital-frontal head circumfer-
ence SDS and weight SDS. There were no statistically
significant differences between the treatment groups for
any of the growth parameters.
Discussion
In PKU, blood Phe concentrations need to be controlled
from birth to prevent neurological sequelae, such as cog-
nitive impairment and mild-to-severe intellectual disabil-
ity, linked to PKU [5, 7]. Until July 2015 there was no
licensed pharmacological treatment available in the EU
for children with PKU aged <4 years, and the standard
of care was a Phe-restricted diet. The results of the
SPARK study, which was the first clinical trial of saprop-
terin in patients 0–4-years-old with BH4-responsive
PKU or mild HPA in Europe, showed that daily dosingwith 10 or 20 mg/kg/day sapropterin in combination with a
Phe-restricted diet led to statistically and clinically signifi-
cant improved dietary Phe tolerance at week 26 compared
with a Phe-restricted diet alone, while maintaining mean
blood Phe concentrations within the protocol-specified
range. These results were consistent with those seen in chil-
dren aged 4–12 years treated with 20 mg/kg/day sapropterin,
in whom the mean amount of Phe supplement tolerated had
increased at 10 weeks of treatment [23]. The results were
also consistent with those reported in a study from
the USA and Canada in children aged 0–6 years old,
in whom 20 mg/kg/day sapropterin treatment lowered
blood Phe concentrations, enabling, in some cases, an
increase in dietary Phe intake [24].
The benefits of initiating sapropterin therapy in pa-
tients younger than 4 years have been highlighted by a
post-marketing study conducted in Japan between 1995
and 2001, which reported that all patients who started
treatment with sapropterin before the age of 4 years
maintained serum Phe concentrations within the recom-
mended range for the duration of the study [25]. Previ-
ous reports have shown that neurocognitive function
was preserved and no neurodevelopmental penalty was
reported in patients who started sapropterin therapy be-
tween 0 and 6 years of age [24], and that treatment with
BH4 may enable relaxation of the dietary regimen, lead-
ing to improved quality of life [26]. Patients with mild
HPA, who comprised almost a half of the population in
this study, retain substantial enzyme activity and will,
therefore, likely respond to sapropterin treatment. How-
ever, the indication for treatment of mild HPA differs
between countries due to weak evidence. US guidelines
recommend treatment at a Phe concentration above
360 μmol/L [10], while other countries start treatment at
Phe concentrations above 600 μmol/L [27].
In this study, the addition of sapropterin to a Phe-
restricted diet in patients <4 years old with BH4-responsive
PAH deficiency significantly improved Phe tolerance com-
pared with a Phe-restricted diet alone. In the sapropterin-
treated group, blood Phe concentrations initially fell at the
beginning of treatment (4 weeks), but they slowly in-
creased over the course of the study to reach concentra-
tions similar to those at baseline by week 12 (Fig. 2), while
increasing dietary Phe-intake. The observed increase in
Phe tolerance reported in patients on the Phe-restricted
diet compared with the tolerance at baseline may be ex-
plained by the fact that the patients in this group were not
at their maximum Phe tolerance in daily practice before
starting the study. This observation confirms the expect-
ation that under the tight control of study conditions using
a strict algorithm of Phe escalation, dietary Phe tolerance
may be further optimized [28]. Because of the potential for
Phe concentrations to drop below either the normal or the
desired therapeutic concentrations owing to the action of
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peutic dose and dietary Phe concentrations was necessary.
The pharmacokinetics of BH4 can be well described by
a one-compartment model that respects the principle of
parsimony and provides accurate estimates that describe
BH4 profiles virtually identical to those from a two-
compartment model evaluated in a previous study [18].
The terminal and absorption half-lives are suggestive of
flip-flop pharmacokinetic behavior, in which absorption
is the rate-limiting step of drug disposition. Sapropterin
exposure was similar across all age groups studied here.
With this in mind, a once-daily dosing regimen is justi-
fied. Weight was the only covariate that had an effect on
the clearance and volume distribution of sapropterin,
meaning that dose adjustments based on weight are
appropriate [14].
The secondary endpoints of growth and neuromotor
development were considered to be normal in the pa-
tient population throughout the study and no differ-
ence between groups was observed, suggesting no
treatment effect on these growth and development
parameters. However, the time scale in the study was
too short to expect clinically meaningful changes in
neuromotor development.
The safety profile for sapropterin was acceptable and
similar to that reported in studies of patients >4 years
old [23] and in those <4 years old [25], with no deaths,
severe TEAEs or withdrawals reported. Although four
patients had SAEs, none of these was deemed to be re-
lated to treatment. The number of TEAEs was similar
between the two groups and was commonly associated
with normal childhood illness.
Conclusion
In conclusion, the addition of sapropterin to a Phe-
restricted diet in patients aged <4 years old with
BH4-responsive PKU, mild PKU or mild HPA was
well tolerated and led to a significant improvement in
Phe tolerance compared with only a Phe-restricted
diet. The pharmacokinetics of sapropterin in patients
aged <4 years are adequately described by a one-
compartment model, and favor once-a-day dosing
with dose adjustment for weight. These data led to
the approval of sapropterin for individuals with BH4-
responsive PKU or mild HPA aged <4 years, and will
thus change treatment management for this subset of
patients in the first week of life.Additional file
Additional file 1: Figure S1. Summary of neuromotor developmental
milestones – ITT population. Data show (a) the proportion of patients
with normal development in the area of assessment at baseline, (b) Week12, and (c) Week 26 treated with sapropterin plus the Phe-restricted diet,
or Phe-restricted diet alone. P-values show comparison of results between
treatment groups at Week 26 using the chi-squared test. Table S1. PAH
genotypes of sapropterin responders (n=37). (DOCX 180 kb)
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